SCHEMBL20119562

SCHEMBL20119562

CNc1nc(NCc2ccco2)c2nc[nH]c2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.50
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
HIF1A Q16665 2/20 0.50
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.50
ADORA3 P0DMS8 1/20 0.50
ALOX15 P16050 1/20 0.50
TSHR P16473 1/20 0.50
KDR P35968 1/20 0.50
CCNB2 O95067 2/20 0.46
CDK1 P06493 2/20 0.46
CCNB1 P14635 2/20 0.46
CCNB3 Q8WWL7 2/20 0.46
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 2/20 0.46
PKM P14618 1/20 0.45
MAPT P10636 5/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17009454 0.85 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AMEN1HIF1ATP53
SCHEMBL16146496 0.85 SMN1; SMN2 (0.53) SMN1; SMN2KMT2AMEN1HIF1ATP53
SCHEMBL16146913 0.83 LMNA (0.56) SMN1; SMN2KMT2AMEN1HIF1ATP53
SCHEMBL20119369 0.83 SMN1; SMN2 (0.50) SMN1; SMN2KMT2AMEN1HIF1ATP53
SCHEMBL13087414 0.82 SMN1; SMN2 (0.68) SMN1; SMN2KMT2AMEN1HIF1ATP53
SCHEMBL16146119 0.82 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AMEN1HIF1ATP53
SCHEMBL16147171 0.82 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AMEN1HIF1ATP53
SCHEMBL16146154 0.82 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AMEN1HIF1ATP53
SCHEMBL16145962 0.82 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AMEN1HIF1ATP53
SCHEMBL16146347 0.82 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AMEN1HIF1ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885MEN1 2691/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885MEN1 2691/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885MEN1 2691/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885MEN1 2691/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885MEN1 2691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.